Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAltamira Therapeutics Ltd. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$2.22 | -$2.22 | -$2.22 |
| Q2 2024 | 1 | -$545.29 | -$545.29 | -$545.29 |
| Q3 2024 | 1 | -$433.95 | -$433.95 | -$433.95 |
| Q1 2025 | 1 | -$433.95 | -$433.95 | -$433.95 |
| Q2 2025 | 1 | -$372.90 | -$372.90 | -$372.90 |
| Q1 2026 | 1 | -$0.48 | -$0.48 | -$0.48 |
| Q2 2026 | 1 | -$0.43 | -$0.43 | -$0.43 |
| Q3 2026 | 1 | -$2.02 | -$2.02 | -$2.02 |
| Q4 2026 | 1 | -$0.49 | -$0.49 | -$0.49 |
| Q1 2027 | 1 | -$0.44 | -$0.44 | -$0.44 |
| Q2 2027 | 1 | -$0.46 | -$0.46 | -$0.46 |
Altamira Therapeutics Ltd. Earnings Date And Information
Altamira Therapeutics Ltd. last posted its earnings results on Tuesday, September 24th, 2024. The company reported $-1.98517 earnings per share for the quarter, topping analysts' consensus estimates of $-2.38032 by $0.39515. The company had revenue of 52,735 for the quarter and had revenue of 0 for the year. Altamira Therapeutics Ltd. has generated $-15 earnings per share over the last year ($-14.8 diluted earnings per share) and currently has a price-to-earnings ratio of -0.02. Altamira Therapeutics Ltd. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, September 24th, 2024 based on prior year's report dates.
Altamira Therapeutics Ltd. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 06/28/2023 | Q2 2023 | -$12.91 | $52,735 | |||
| 03/30/2023 | Q1 2023 | -$12.97 | $52,735 | |||
| 05/16/2023 | Q4 2022 | -$2.89 | $0 | |||
| 09/29/2022 | Q3 2022 | -$199.86 | $-458,691 | |||
| 11/30/2022 | Q2 2022 | -$106.32 | $145,399 | |||
| 11/30/2022 | Q1 2022 | -$106.32 | $145,399 | |||
| 04/12/2022 | Q4 2021 | $164.89 | $0 | |||
| 09/29/2021 | Q3 2021 | -$149.92 | $0 | |||
| 03/31/2021 | Q2 2021 | -$438.94 | -$108.47 | 330.47 | $0 | |
| 03/31/2021 | Q1 2021 | -$438.94 | -$108.47 | 330.47 | $0 | |
| 03/31/2021 | Q4 2020 | -$438.94 | -$148.91 | 290.03 | $237,000 | |
| 09/29/2020 | Q3 2020 | -$510.79 | -$148.91 | 361.88 | $0 | |
| 09/17/2020 | Q2 2020 | -$115.96 | $0 | |||
| 09/17/2020 | Q1 2020 | -$115.96 | $0 | |||
| 04/16/2020 | Q4 2019 | -$32.00 | -$83.44 | -51.44 | $-56,000 | |
| 09/29/2019 | Q3 2019 | $0.00 | $0 | |||
| 06/30/2019 | Q2 2019 | -$165.85 | $0 | |||
| 03/30/2019 | Q1 2019 | $0.00 | $0 | |||
| 03/14/2019 | Q4 2018 | -$485.21 | $1.27 M | |||
| 09/30/2018 | Q3 2018 | -$569.22 | $0 |
Altamira Therapeutics Ltd. Earnings: FAQ's
When is Altamira Therapeutics Ltd.'s earnings date?
Altamira Therapeutics Ltd. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, September 24th, 2024 based off last year's report dates.
Did Altamira Therapeutics Ltd. beat their earnings estimates last
quarter?
In the previous quarter, Altamira Therapeutics Ltd. (:CYTO) reported $-1.98517 earnings per share (EPS) to beat the analysts' consensus estimate of $-2.38032 by $0.39515.
How can I listen to Altamira Therapeutics Ltd.'s earnings conference
call?
The conference call for Altamira Therapeutics Ltd.'s latest earnings report can be listened to online.
How can I read Altamira Therapeutics Ltd.'s conference call transcript?
The conference call transcript for Altamira Therapeutics Ltd.'s latest earnings report can be read online.
How much profit does Altamira Therapeutics Ltd. generate each year?
Altamira Therapeutics Ltd. (:CYTO) has a recorded net income of $0. Altamira Therapeutics Ltd. has generated $-14.81 earnings per share over the last four quarters.
What is Altamira Therapeutics Ltd.'s price-to-earnings ratio?
Altamira Therapeutics Ltd. (:CYTO) has a price-to-earnings ratio of -0.02 and price/earnings-to-growth ratio is -0.